• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Reallocation targets


<











The targets include anyone over 50 .... they save a bunch in retirement dollars and don't want any experience any more.

In the labs, no doubt about it. What they are doing when acquiring fancy million dollar machines, is to request the vendor to supply a warm body to push it's buttons for the first six months. Vendor supplies warm body, meets contractual obligations.

Lilly pays up and is left with a very expensive boat anchor. Then, hire 4-5 FDEs to play Keystone Cops while a PhD pecks at her laptop, chronicling her successes of getting results through people. Look at glassdoor, what current employees say. It's shocking. Of course some of the posts are no doubt faked by HR.

Management is incompetent, in sales, in the lab, and in legal. The stock was pumped for a while, I made a few bucks on a short position but should have hung in there for the long ride down. If you want to see a good company, check out Novartis. A company that has the balls to have active research in the real biotech centers, like Cambridge and the SF bay.